Kymera Therapeutics Inc. (KYMR) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (57/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+58.8% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
Kymera Therapeutics Inc. (KYMR) advanced +0.07% to $122.60 as options desks priced 54% call premium vs. 46% put protection around the $120 max-pain magnet. Accounting Warning: Paper earnings outpaced operating cash flow (+58.8% (NI vs OCF)) as receivables rose.
Truist Securities analyst Srikripa Devarakonda reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $136 to $150.
RBC Capital analyst Brian Abrahams maintains Kymera Therapeutics (NASDAQ:KYMR) with a Sector Perform and raises the price target from $112 to $116.
Moby summary of Kymera Therapeutics, Inc.'s Q3 2026 earnings call
KT-579 IRF5 degrader hit 94% degradation in Phase I trials.
Kymera Therapeutics (NASDAQ:KYMR) reported third-quarter results and outlined progress across its clinical pipeline, including phase I healthy-volunteer data for KT-579, an oral degrader targeting IRF5 for autoimmune dis
BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $134 to $139.
Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDTCompany ParticipantsJustine Koenigsberg - Vice President of Investor...
KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile KT-579 LUMORA Phase 1b trial in lupus patients p
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.27) by 3.94 percent. This is a 40.43 percent decrease over losses of $(0.94) per share
WATERTOWN, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological d
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -16.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KYMR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KYMR. Explore sector supply chains on /butterfly.
Why KYMR Stock advanced +0.07% Today — RQD Quant Desk Flash. Accounting Warning: Paper earnings outpaced operating cash flow (+58.8% (NI vs OCF)) as receivables rose.